Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease

This study has been completed.
Information provided by (Responsible Party):
University of Western Ontario, Canada Identifier:
First received: March 17, 2008
Last updated: May 12, 2016
Last verified: May 2016
The purpose of this study is to evaluate the use of phlebotomy (blood taking)as a treatment for patients with non-alcoholic fatty liver disease.

Condition Intervention
Non-alcoholic Fatty Liver Disease
Procedure: Phlebotomy

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease

Resource links provided by NLM:

Further study details as provided by University of Western Ontario, Canada:

Primary Outcome Measures:
  • Severity of liver disease [ Time Frame: 6 months after final treatment ]

Secondary Outcome Measures:
  • Severity of metabolic disease [ Time Frame: 6 months after final treatment ]

Enrollment: 45
Study Start Date: January 2009
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Iron depletion via phlebotomy
Procedure: Phlebotomy
Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
Other Name: Venesection

Detailed Description:
In this study phlebotomy will be evaluated as a therapy for non-alcoholic fatty liver disease (NAFLD), a common and important cause of liver disease. Phlebotomy has been used for many years in the treatment of disorders of iron overload such as hemochromatosis, where it is well tolerated and improves symptoms and survival. There is some evidence that it is also effective in treating NAFLD. However, previous studies have not evaluated whether phlebotomy improves liver biopsy findings. We will measure the severity disease in NAFLD patients prior to phlebotomy therapy and again at the end of treatment. This will allow us to accurately determine the benefit of this therapy in these patients.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients 18y or older
  • Diagnosis of Non-alcoholic Fatty Liver Disease

Exclusion Criteria:

  • Unable or unwilling to provide informed consent
  • Alcohol consumption of >10g/day for women and >20g/day for men
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00641524

Canada, Ontario
London Health Sciences Centre
London, Ontario, Canada, N6A 5A5
Sponsors and Collaborators
University of Western Ontario, Canada
Principal Investigator: Melanie D Beaton, MD University of Western Ontario, Canada
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University of Western Ontario, Canada Identifier: NCT00641524     History of Changes
Other Study ID Numbers: beatonclf
Study First Received: March 17, 2008
Last Updated: May 12, 2016

Keywords provided by University of Western Ontario, Canada:
Non-alcoholic fatty liver disease
liver fibrosis
metabolic syndrome
iron overload

Additional relevant MeSH terms:
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases processed this record on May 25, 2017